A new 2-drug combination offers more than double the weight loss of Orlistat, the only drug currently FDA-approved for long-term obesity treatment. In a study appearing online in The Lancet today, researchers from Duke University Medical Center and other centers report that combining phentermine (approved for short-term obesity treatment) and topiramate (approved for epilepsy and migraine) resulted in obese volunteers shedding up to 10 percent of their body weight during the one-year study. Here’s a look at the study findings:
What are the risks? The main side effects reported in the study were constipation, dry mouth and a mild pins-and-needles tingling sensation. There was also a higher rate of anxiety and depression in people who received the drug combination, versus the placebo group, with those on the higher dose twice as likely to experience these problems as those on the lower dose. Sourced by Yahoo.com (Why Not Do It Natural )http://www.sparkitupnow.com
What are the risks? The main side effects reported in the study were constipation, dry mouth and a mild pins-and-needles tingling sensation. There was also a higher rate of anxiety and depression in people who received the drug combination, versus the placebo group, with those on the higher dose twice as likely to experience these problems as those on the lower dose. Sourced by Yahoo.com (Why Not Do It Natural )http://www.sparkitupnow.com
No comments:
Post a Comment